CN101182585A - 一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒 - Google Patents
一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒 Download PDFInfo
- Publication number
- CN101182585A CN101182585A CNA2007101793299A CN200710179329A CN101182585A CN 101182585 A CN101182585 A CN 101182585A CN A2007101793299 A CNA2007101793299 A CN A2007101793299A CN 200710179329 A CN200710179329 A CN 200710179329A CN 101182585 A CN101182585 A CN 101182585A
- Authority
- CN
- China
- Prior art keywords
- sequence
- primer
- bar code
- deoxyribonucleotide
- kinds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 20
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 6
- 239000000523 sample Substances 0.000 claims abstract description 99
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 17
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 8
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims abstract description 7
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 60
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 60
- 239000002773 nucleotide Substances 0.000 claims description 40
- 125000003729 nucleotide group Chemical group 0.000 claims description 40
- 238000009396 hybridization Methods 0.000 claims description 39
- 230000000869 mutational effect Effects 0.000 claims description 35
- 238000001514 detection method Methods 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 23
- 230000003321 amplification Effects 0.000 claims description 21
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 21
- 208000002672 hepatitis B Diseases 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 16
- 238000007403 mPCR Methods 0.000 claims description 13
- 150000007523 nucleic acids Chemical group 0.000 claims description 12
- 230000008878 coupling Effects 0.000 claims description 10
- 238000010168 coupling process Methods 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 238000003149 assay kit Methods 0.000 claims 5
- 230000035772 mutation Effects 0.000 abstract description 13
- 108060002716 Exonuclease Proteins 0.000 abstract description 2
- 102000013165 exonuclease Human genes 0.000 abstract description 2
- 108700024845 Hepatitis B virus P Proteins 0.000 description 45
- 230000008859 change Effects 0.000 description 36
- 239000013612 plasmid Substances 0.000 description 33
- 238000004519 manufacturing process Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000003908 quality control method Methods 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 238000012408 PCR amplification Methods 0.000 description 11
- 238000011144 upstream manufacturing Methods 0.000 description 10
- 125000003368 amide group Chemical group 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 229960001627 lamivudine Drugs 0.000 description 7
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 7
- 239000002751 oligonucleotide probe Substances 0.000 description 7
- 239000006210 lotion Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 5
- 238000006384 oligomerization reaction Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229960000980 entecavir Drugs 0.000 description 4
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- -1 Adefovir ester Chemical class 0.000 description 3
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229960001997 adefovir Drugs 0.000 description 2
- 229960003205 adefovir dipivoxil Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101150084044 P gene Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
核苷类似物 | 耐药位点 | 参考文献 |
拉米夫定(lamivudine) | M 204 I | 1.Anna SF.et,al..Chronic Hepatieis B:Update ofRecommendations.AASLD PRACTICE GUIDELINE.20062.Liaw YF,et,al.Effects of extended lamivudine therapy inAsian patients with chronic hepatitis B.Asia HepatitisLamivudine Study Group.Gastroenterology.2000,119(1):172-803.Paik YH,et,al.Emergence of YMDD motif mutant ofhepatitis B virus during short-term lamivudine therapyin South Korea.J Hepatol,2001,35(1):92-98. |
M 204 V | ||
M 204 S | ||
L 180 M | ||
L 80 V | ||
L 80 I | ||
V 173 G | ||
V 173 L | ||
阿德福韦酯(adefovirdipivoxil) | A 181 T | 1.Nna S.F.et,al.Chronic Hepatitis B:Update ofRecommendations.AASLD PRACTICE GUIDELINE.2.S Locarninil,et,al.Adefovir Resistancereport:4 yearsupdate.40th Annual Meeting of the European Association forthe Study of the Liver April 13-17,2005.3.Owy,C.et,al.Detection of rtN236T and rtA181V/TMutations Associated with Resistance to Adefovir Dipivoxilin Samples from patients with Chronic Hepatitis B Virusinfection by the INNO-LIPA HBV DR Line Probe Assay(Version2).J.Clin.Microbiol.2006(44):1994-1997. |
A 181 V | ||
N 236 T | ||
恩替卡韦(Entecavir) | I 169 T | 1.Reported by Jules Levin Entecavir Resistance in LamivudineResistant Pahents,EASL 39th Annual European Association forthe Study of the Liver Conference.Berlin,Germany,April14-18,2004.2.Monis Sherman,et,al.Entecavir for Treahmerd ofLamivudine-Refractory,HBeAg-Positive Cluonic HepaditisB,Gastroenterology 2006,130:2039-20493.STEPHEN LOCARNINI.Relevance of HBV mutations in severityprogression of chronic hepatitis B.Journal ofGastroenterology and Hepatology.2004(19):S108. |
T 184 G | ||
S 202 I | ||
M 250 I |
突变形式 | 引物名称 | 引物序列在序列表中的编号 | 探针名称 |
rtL 180 M | 180L-WT | 2 | 180L |
180M-MU | 3 | 180M | |
rtA 181 T | 181A-WT | 4 | 181A |
181T-MU | 5 | 181T | |
rtA 181 V | 181A-WT | 4 | 181A |
181V-MU | 6 | 181V | |
rtM 204 I | 204M-WT | 7 | 204M |
204I-MU | 8 | 204I | |
rtM 204 V | 204M-WT | 7 | 204M |
204V-MU | 9 | 204V | |
rtM 204 S | 204M-WT | 7 | 204M |
204S-MU | 10 | 204S | |
rtN 236 T | 236N-WT | 11 | 236N |
236T-MU | 12 | 236T | |
共用引物(UF) | 1 |
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101793299A CN101182585B (zh) | 2007-12-12 | 2007-12-12 | 一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101793299A CN101182585B (zh) | 2007-12-12 | 2007-12-12 | 一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101182585A true CN101182585A (zh) | 2008-05-21 |
CN101182585B CN101182585B (zh) | 2010-06-09 |
Family
ID=39448010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101793299A Active CN101182585B (zh) | 2007-12-12 | 2007-12-12 | 一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101182585B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102230025A (zh) * | 2011-06-08 | 2011-11-02 | 中国人民解放军第四军医大学 | 一种用于乙型肝炎病毒基因耐药突变检测的试剂盒及检测方法 |
CN102676654A (zh) * | 2011-03-17 | 2012-09-19 | 中国科学院微生物研究所 | 一种检测基因突变的方法 |
CN102994519A (zh) * | 2011-09-15 | 2013-03-27 | 蔡志明 | 化学合成的HBV 1.2x基因组、表达系统及其构建方法 |
CN103088151A (zh) * | 2012-08-15 | 2013-05-08 | 浙江大学 | 用于乙型肝炎病毒四色荧光定量pcr检测的试剂盒及应用 |
CN104846074A (zh) * | 2015-03-26 | 2015-08-19 | 珠海赛乐奇生物技术有限公司 | 用于torch检测的探针、基因芯片和试剂盒 |
CN107022607A (zh) * | 2017-03-16 | 2017-08-08 | 北京博奥晶典生物技术有限公司 | 通过碱基错配解决多重pcr时等位基因扩增不平衡的方法 |
CN107937507A (zh) * | 2017-11-17 | 2018-04-20 | 中国人民解放军第三〇二医院 | 一种可溶性微针贴片及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1834261A (zh) * | 2005-11-15 | 2006-09-20 | 北京博奥生物芯片有限责任公司 | 基因分型芯片及其制备方法与应用 |
WO2007084567A2 (en) * | 2006-01-17 | 2007-07-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Detection and discrimination of hepatitis c virus, human immunodeficiency virus type-1 and hepatitis b virus |
CN100510105C (zh) * | 2006-02-08 | 2009-07-08 | 博奥生物有限公司 | 一种序列特异性寡核苷酸探针及其应用 |
CN1896284B (zh) * | 2006-06-30 | 2013-09-11 | 博奥生物有限公司 | 一种鉴别等位基因类型的方法 |
-
2007
- 2007-12-12 CN CN2007101793299A patent/CN101182585B/zh active Active
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102676654B (zh) * | 2011-03-17 | 2014-09-24 | 中国科学院微生物研究所 | 一种检测基因突变的方法 |
CN102676654A (zh) * | 2011-03-17 | 2012-09-19 | 中国科学院微生物研究所 | 一种检测基因突变的方法 |
CN102230025A (zh) * | 2011-06-08 | 2011-11-02 | 中国人民解放军第四军医大学 | 一种用于乙型肝炎病毒基因耐药突变检测的试剂盒及检测方法 |
CN102230025B (zh) * | 2011-06-08 | 2014-04-23 | 中国人民解放军第四军医大学 | 一种用于乙型肝炎病毒基因耐药突变检测的试剂盒及检测方法 |
CN102994519A (zh) * | 2011-09-15 | 2013-03-27 | 蔡志明 | 化学合成的HBV 1.2x基因组、表达系统及其构建方法 |
CN102994519B (zh) * | 2011-09-15 | 2016-06-15 | 蔡志明 | 化学合成的HBV 1.2x基因组、表达系统及其构建方法 |
CN103088151A (zh) * | 2012-08-15 | 2013-05-08 | 浙江大学 | 用于乙型肝炎病毒四色荧光定量pcr检测的试剂盒及应用 |
CN103088151B (zh) * | 2012-08-15 | 2014-07-23 | 浙江大学 | 用于乙型肝炎病毒四色荧光定量pcr检测的试剂盒及应用 |
CN104846074A (zh) * | 2015-03-26 | 2015-08-19 | 珠海赛乐奇生物技术有限公司 | 用于torch检测的探针、基因芯片和试剂盒 |
CN104846074B (zh) * | 2015-03-26 | 2017-12-22 | 珠海赛乐奇生物技术股份有限公司 | 用于torch检测的探针、基因芯片和试剂盒 |
CN107022607A (zh) * | 2017-03-16 | 2017-08-08 | 北京博奥晶典生物技术有限公司 | 通过碱基错配解决多重pcr时等位基因扩增不平衡的方法 |
CN107022607B (zh) * | 2017-03-16 | 2019-01-22 | 北京博奥晶典生物技术有限公司 | 通过碱基错配解决多重pcr时等位基因扩增不平衡的方法 |
CN107937507A (zh) * | 2017-11-17 | 2018-04-20 | 中国人民解放军第三〇二医院 | 一种可溶性微针贴片及其制备方法 |
CN107937507B (zh) * | 2017-11-17 | 2021-06-01 | 中国人民解放军第三〇二医院 | 一种可溶性微针贴片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101182585B (zh) | 2010-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105164280B (zh) | 使用阻断性寡核苷酸进行dna扩增的方法 | |
CN101182585B (zh) | 一种鉴别hbv基因突变类型的方法及其专用芯片与试剂盒 | |
US9644233B2 (en) | Loop-shaped primer used in nucleic acid amplification and the use thereof | |
CN107034277A (zh) | 一种检测低丰度基因突变的方法 | |
CN113151519B (zh) | 用于同时检测幽门螺旋杆菌及其耐药基因的多重荧光pcr试剂及其应用 | |
KR101644773B1 (ko) | 어류 에드와드 감염증과 연쇄구균 감염증 원인세균의 판별 및 검출용 유전자 마커, 및 이를 이용한 원인세균의 판별 및 검출 방법 | |
CN110791577A (zh) | 一种检测结核分枝杆菌异烟肼耐药突变基因的试剂盒及方法 | |
CN104328182A (zh) | 一种用于检测pdgfra基因热点突变的引物、探针、锁核苷酸探针、试剂盒及检测方法 | |
CN115058543B (zh) | 一组鉴别Delta变异毒株和Omicron变异毒株的引物组和试剂盒 | |
CN107787370A (zh) | Rna的分子检测 | |
CN108374042A (zh) | 离子激流基因组测序 | |
CN105177118B (zh) | 检测人egfr基因突变的引物和探针体系及试剂盒 | |
CN108060213B (zh) | 基于探针导向的重组酶介导的等温扩增法检测snp位点用探针和试剂盒 | |
CN102286616A (zh) | 一种检测结核分枝杆菌异烟肼耐药基因突变的方法及试剂盒 | |
KR101287431B1 (ko) | 표적 유전자의 다양한 변이가 존재하는 유전자 영역을 증폭하기 위한 프라이머 조성물, 이를 이용한 표적 유전자 증폭 방법 및 이를 포함하는 pcr 증폭 키트 그리고 이를 이용한 표적 유전자의 유전자형 분석방법 | |
CN109234367A (zh) | 一种针对乙型肝炎病毒ymdd基序区耐药突变的试剂盒 | |
CN102057055B (zh) | 分支杆菌的快速检测 | |
CN103014135A (zh) | 一种鉴定结核分枝杆菌的方法 | |
AU2011209624B2 (en) | Methods and kits used in the detection of fungus | |
KR102683325B1 (ko) | 헬리코박터 파일로리(Helicobacter pylori) 유전형 판별용 PNA 프로브 및 이를 이용한 헬리코박터 파일로리 유전형 판별방법 | |
CN106520948B (zh) | 一种可视化检测基因序列中单核苷酸多态性位点的反向探针、试剂盒及其检测方法 | |
CN110819725A (zh) | 一种基于人工模拟核酸分子信标的检测幽门螺杆菌克拉霉素耐药位点的方法与试剂盒 | |
CN115323075A (zh) | 一种检测鸡传染性支气管炎病毒及基因分型的rt-raa引物探针组、试剂盒及其应用 | |
CN112501166A (zh) | 一种化学修饰的高稳定性rna及试剂盒和方法 | |
CN114875116B (zh) | 一种自淬灭荧光的引物及其设计方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: CAPITALBIO CORPORATION CO., LTD. Free format text: FORMER NAME: CAPITALBIO CORPORATION |
|
CP01 | Change in the name or title of a patent holder |
Address after: 102206 Beijing City, Changping District Life Science Park Road No. 18 Patentee after: CAPITALBIO CORPORATION Patentee after: Tsinghua University Address before: 102206 Beijing City, Changping District Life Science Park Road No. 18 Patentee before: Capitalbio Corporation Patentee before: Tsinghua University |
|
TR01 | Transfer of patent right |
Effective date of registration: 20180320 Address after: 101111 Beijing branch of Beijing economic and Technological Development Zone Street 88 Hospital No. 10 Building Room 101 Co-patentee after: Tsinghua University Patentee after: CAPITALBIO TECHNOLOGY CO., LTD. Address before: 102206 Beijing City, Changping District Life Science Park Road No. 18 Co-patentee before: Tsinghua University Patentee before: CAPITALBIO CORPORATION |
|
TR01 | Transfer of patent right |